Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.

@article{Boissy2008PulseTW,
  title={Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.},
  author={Patrice Boissy and Thomas Levin Andersen and Thomas J. Lund and Kasia Kupisiewicz and Torben Plesner and J. M. Delaiss{\'e}},
  journal={Leukemia research},
  year={2008},
  volume={32 11},
  pages={1661-8}
}
Myeloma bone disease is due to bone degradation by osteoclasts, and absence of repair by bone forming osteoblasts. Recent observations suggest that the anti-myeloma drug bortezomib, a proteasome inhibitor, stimulates bone formation and may inhibit bone resorption. Here, we tested bortezomib on cultured osteoclasts in conditions mimicking the pulse treatment used in the clinic, thereby avoiding continuous proteasome inhibition and unselective toxicity. A 3 h pulse with 25 nM bortezomib followed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…